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Abstract The aim of the study was to investigate trastuzumab
anti-tumor efficacy and its correlation with HER-2 status in
primary xenograft models derived from Chinese patients with
gastric adenocarcinoma. Patient-derived gastric adenocarcino-
ma xenograft (PDGAX) mouse models were firstly generated
by implanting gastric adenocarcinoma tissues from patients
into immune deficient mice. A high degree of histological
and molecular similarity between the PDGAX mouse models
and their corresponding patients’ gastric adenocarcinoma tis-
sues was shown by pathological observation, HER-2 expres-
sion, HER-2 gene copy number, and mutation detection.
Based on Hoffmann’s criteria in gastric cancer, three models
(PDGAX001, PDGAX003 and PDGAX005) were defined as
HER-2 positive with fluorescence in situ hybridization (FISH)
amplification or immunohistochemistry (IHC) 2+/ 3+, while
two models (PDGAX002, PDGAX004) were defined as
HER-2 negative. Upon trastuzumab treatment, significant tu-
mor regression (105 % TGI) was observed in model
PDGAX005 (TP53 wt), while moderate sensitivity (26 %
TGI) was observed in PDGAX003, and resistance was ob-
served in PDGAX001, 002 and 004. A significant increase
in HER-2 gene copy number was only observed in
PDGAX005 (TP53 wt). Interestingly, trastuzumab showed
no efficacy in PDGAX001 (HER2 IHC 3+ and FISH ampli-
fication, but with mutant TP53). Consistent with this finding,
phosphor-HER2 modulation by trastuzumab was observed in
model PDGAX005, but not in PDGAX001.
Keywords HER2 . Gastric carcinoma . Trastuzumab .
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Introduction
Gastric cancer (GC) is the second most common cancer and
leading cause of cancer mortality worldwide [1–4]. Early
stage patients with GC usually show no specific symptoms
and as a consequence, GC patients often present with ad-
vanced disease upon diagnosis, especially in countries where
gastric cancer screening is not routinely performed [4, 5].
Surgery remains the fundamental treatment option for re-
sectable gastric cancer. However, even after curative surgery,
local and distant recurrence rates are still high. Advanced-
stage gastric cancer is associated with poor prognosis and
low 5-year survival rates (5–20 %) [6]. Although adjuvant
chemotherapy using epirubicin, cisplatin, and 5-flurouracil
(5-FU) has gradually become standard-of-care therapy for
GC patients in many countries [7], most patients with inoper-
able or metastatic disease require palliative treatment and have
a median overall survival of less than 1 year and a limited
chance of long-term survival [6, 8].
Due to recent genomic and proteomic advances and im-
proved understanding of the key molecular pathways in can-
cer, molecular targeted therapies have emerged as additional
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treatment options in clinical practice. HER2 protein overex-
pression is increasingly recognized as a frequent molecular
abnormality, known to be driven byHER-2 gene amplification
in breast cancer [9]. Overexpression of the HER2 protein and
amplification of the HER-2 gene in gastric cancer were first
described in 1986 [10]. In recent years, HER-2 has gradually
become a new prognostic factor and a novel therapeutic target
in GC [9].
Trastuzumab is a recombinant humanized monoclonal an-
tibody targeted against the HER2 extracellular domain [11].
The ‘Trastuzumab in gastric cancer’ (ToGA) study was the
first randomized, controlled phase III trial to evaluate
trastuzumab efficacy and safety in HER2-positive advanced
gastric cancer [12]. In this trial, 22.1 % of the patients were
identified as positive for HER-2 protein expression [8] and the
median overall survival was significantly improved after
trastuzumab treatment plus chemotherapy, compared to che-
motherapy alone (13.8 vs 11.1 months) [13]. Importantly,
trastuzumab showed no significant concomitant increase in
treatment side effects [13], leading to its approval in 2010 in
the EU and US for use in combination with 5-FU or capecit-
abine plus cisplatin for the first-line treatment of patients with
HER2-positive metastatic adenocarcinoma of the stomach or
GE junction [1, 5]. The European Medicines Agency recom-
mended immunohistochemistry (IHC) as the first-line test for
HER-2, with patients scoring 3+ eligible for trastuzumab ther-
apy and 2+ cases classified as equivocal and necessitating a
confirmatory fluorescence in situ hybridization (FISH) result
[14]. The US FDA defined positivity by utilizing the eligibil-
ity criteria of the ToGA trial: IHC 3+ or 2+ plus FISH ampli-
fication [14]. However, unlike breast cancer [15], accurate and
finalized HER-2 scoring criteria for gastric cancer patient se-
lection still remains a subject for debate [16].
Herein we describe the generation and characterization of
xenograft mouse models derived directly from patients’ gas-
tric adenocarcinoma tissues. Furthermore, we use these novel
clinically relevant models to evaluate the current HER-2 scor-
ing system and to explore the opportunity for trastuzumab
targeted therapy in gastric carcinoma patients.
Materials and Methods
Patients and Tissue Samples
Five treatment-naïve gastric adenocarcinoma patient samples
were obtained intraoperatively during gastrectomy resection
at the Renji Hospital, Shanghai, China. Freshly harvested gas-
tric adenocarcinoma specimens from patient tumors were sep-
arated into three parts: the first part was transferred to
medium-containing antibiotics immediately after surgical re-
section under sterile conditions, then transported to an animal
facility within 2 h for implantation into immune deficient
mice; the second part was snap frozen immediately in liquid
nitrogen for DNA/ RNA extraction; and the third part was
fixed in formalin and embedded in paraffin for pathological
and IHC analysis. All the samples were firstly evaluated by
pathologist for quality control purposes. Informed consent
was obtained from all patients. This study was approved by
the ethics board of Renji Hospital, Shanghai Jiaotong
University.
Establishment of Patient Derived Gastric Adenocarcinoma
Xenograft (PDGAX) Mouse Models
Eight to 10 week old female nude (nu/nu) mice and severe
combined immune deficient (SCID) mice (Vital River, Bei-
jing, China) were used for the generation of xenograft models
in this study. Animals were kept in a controlled light–dark
cycle (12 h-12 h). The PDGAX mouse models were
established from fresh patient gastric adenocarcinoma (GA)
tissues surgically resected from GC patients. Patient’s GA
tissues (F0 tissue) were cut into fragments of approximately
15 mm3 and implanted subcutaneously via Trocar needle into
female SCIDmice within 2 h after surgery. The patient tumor-
engrafted mice were observed daily for 90 days. Once tumors
started to grow, subcutaneous caliper measurements were tak-
en weekly. Around 500 mm3 GA tumors was harvested from
each tumor-bearing mice and further implanted in another
batch of female nude mice. After three consecutive mouse-
to-mouse passages, the xenograft was considered to be stable
and submitted for full characterization, including histopatho-
logical analysis, HER-2 expression by FISH and IHC assays,
and mutation detection of AKT1, FGFR4, PIK3CA, PTCH,
PTEN and TP53. The tumor specimens in each passage of
the tumor-bearing mice were harvested and divided into three
parts. The first part was implanted into immune deficient mice
for the next generation of the xenograft model; the second part
was snap frozen in liquid nitrogen for DNA/RNA extraction;
and the third part was fixed in 10% buffered formalin for 24 h
and embedded in paraffin for IHC analysis. Surplus fresh tu-
mor tissues at passage 3–5 were frozen with 20 % FCS in
liquid nitrogen for futuremodel recovery. The PDGAXmouse
models were maintained in nude mice within ten passages for
efficacy studies. All animal experiments were performed in
accordance with IACUC-approved guidelines.
H&E Staining
All the xenograft and primary tissues were fixed in 10 % buff-
ered formalin within 30 min after resection. Tissues were
processed using a routine procedure after 24 h fixation. Sec-
tioned slides were stained with hematoxylin and eosin, and
then reviewed by pathologist to confirm the GA diagnosis.
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Immunohistochemistry
All incubations were performed at room temperature
and all washing steps were performed with TBST. Tis-
sues sectioned at 4 μm were firstly dewaxed and
rehydrated. Antigen retrieval was performed using a
pressure cooker at 110 °C for 5 min in retrieval buffer
(S2367, DAKO). Endogenous peroxidase activity was
blocked with 3 % hydrogen peroxide (S2023, DAKO).
Sections were then incubated with HER-2 antibody
(HerceptestTM, DAKO) for 30 min and phospho-HER2
(pHER2) antibody (1:600, Epitomics 2521–1) for
60 min, respectively. Finally, immunocomplexes were
detected by incubation with Envision system (DAKO
K5204) for 30 min and diaminobenzidine (K3468,
DAKO) for 10 min.
In the present study, the IHC scoring criteria on human
gastric cancer followed Hoffman’s criteria [16]: no staining or
<10 % tumor cell positive staining was defined as 0/negative;
faintly or barely perceptible staining on >10 % tumor cell
membrane was defined as 1+; weak to moderate positive
staining on >10% tumor cells was defined as 2+; and cohesive
moderate to strong staining on the membrane was defined as
3+.
Fluorescence in Situ Hybridization
HER2/CEP17 FISH probes were obtained from Vysis
(Cat #30-161060) and FISH assays were performed as
per the manufacturer’s instructions. In brief, TMA sec-
tions were dewaxed, dehydrated, and 10 μl HER2/
CEP17 p r ob e s we r e app l i e d . S e c t i o n s we r e
codenaturated together with probes at 75 °C for
4 min, then incubated overnight at 37 °C. Subsequently,
probes were washed off twice sequentially with 0.3 %
NP40/1×SSC at 75.5 °C for 5 min, 2×SSC at room
temperature for 2 min, and then dehydrated and air-
dried. Sections were mounted in 0.3 μg/ml DAPI
mounting medium (diluted from Vector, Cat #H-1200),
and stored at 4 °C (avoiding light) for at least 30 min
Fig. 1 PDGAX model tumor
growth curves. All five patient-
derived gastric adenocarcinoma
samples showed growth after
subcutaneous implantation in
SCID mice and subsequently in
nude mice
Table 1 Patient and PDGAX mouse model information







Grade Model ID FISH IHC AKT1 FGFR4 PI3KCA PTCH PTEN TP53 Trastuzumab P value
M/57 AC III III PDGAX001 AMP +++ WT WT WT WT WT Mutated 19 0.0904
M/54 AC IV III PDGAX002 Non AMP ++ WT WT WT WT WT WT 0 0.3318
M/51 AC II II PDGAX003 Non AMP +++ WT WT WT WT WT WT 26 0.0626
M/58 AC IV III PDGAX004 Non AMP – WT WT WT WT WT WT 9 0.3309
F/62 AC III III PDGAX005 AMP +++ WT WT WT WT WT WT 107 <0.0001
M male, F female, AC adenocarcinoma
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prior to scoring. In each case, 50 tumor nuclei were
evaluated. Intact interphase tumor nuclei identified by
DAPI staining were evaluated, and gene (red signal)
and CEP17 (green signal) copy numbers in each nucleus
were assessed. An absolute HER-2 gene copy number
lower than four or an HER-2/CEP17 ratio of less than
1.8 was considered HER-2 negative. HER-2 copy num-
ber between 4 and 6, or a HER-2/CEP17 ratio between
1.8 and 2.0 was considered HER-2 equivocal. Cases
showing a tight gene cluster of HER-2 signals, an
Fig. 3 HER-2 IHC and FISH analysis. Representative images showing
HER-2 IHC and FISH results on PDGAX mouse models (top row) and
matched human primary tumor tissues (bottom row). HER-2 strong
staining (3+) and FISH amplification (AMP) were detected in models
PDGAX005 and PDGAX001 and matched primary tumor tissues.
PDGAX001, PDGAX002, PDGAX003, and PDGAX004 were shown
to be HER-2 IHC (0~3+) and FISH non-AMP. For FISH data, red
signals represent HER2 and green signals represent CEP17
Fig. 2 Histological evaluation of the PDGAX mouse models and matched human primary tumors. Representative images showing similar histological
features (adenocarcinoma) between each PDGAX mouse model (top row) and the corresponding patient GA tissue (bottom row). AC: adenocarcinoma
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average gene copy number of HER-2>6, or a HER-2/
CEP17 fluorescence ratio≥2 were considered positive
for gene amplification. The above criteria was based
on the Hoffmann criteria in GC [16] and other investi-
gations [17, 18].
Trastuzumab Antitumor Efficacy Studies
For therapeutic experiments, suitable tumor-bearing, HER-2
positive mice in the tumor volume range of 150 to 250 mm3
were sorted randomly (8 animals per group) and assigned to
vehicle control or trastuzumab treatment groups (Roche, Chi-
na, 15 mg/kg/twice weekly intraperitoneally). Nude mouse
subcutaneous tumor volumes and body weights were mea-
sured twice per week. Tumor volume was calculated from
two perpendicular diameters using the formula: V=(length+
[width]2) /2. The calculated volumes were standardized to the
values at the first treatment day. Percentage of tumor growth
inhibition (%TGI) was calculated with the formula [1 –
(change of tumor volume in treatment group/change of tumor
volume in control group)]×100, which was used for the eval-
uation of anti-tumor efficacy.
Fig. 4 Trastuzumab anti-tumor
efficacy in PDGAX models.
Xenograft tumors from stable
passages of the PDGAX models
were implanted subcutaneously
into nude mice and treated with
vehicle control or trastuzumab
15 mg/kg twice a week for two or
4 weeks, based on tumor growth
rates in the different models when
tumors reached 150~250 mm3
post implantation. Significant
tumor regression was only
observed in model PDGAX005
(TGI 105 %), while moderate or




volumes were measured twice a
week. Tumor growth inhibition
(%TGI) was calculated based on
tumor volumes of the control and
treatment groups
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Screening of Gene Mutations
Formalin-fixed paraffin-embedded tumor blocks were
reviewed for quality and tumor content. A single repre-
sentative block, containing both PDGAX mouse model
and the corresponding patient GA sample (each contain-
ing at least 70 % of neoplastic cells) was screened for
gene mutations. Genomic DNA was extracted using the
QIAamp Mini kit (Qiagen) as per the manufacturer’s in-
structions. ‘Hot spot’ mutations in AKT1 (exon 18, 19, 20,
21), FGFR4 (exon 2 and 3), PIK3CA (exon 10 and 15),
PTCH (exon 1, 2), PTEN (exon 1,2) and TP53 genes
(exon 5 and 7) were screened using amplification refrac-
tory mutation system (ARMS, Amoy diagnostics, Fujian,
China) and mutant-enriched liquid chip PCR method
(SurExam Bio-Tech, Guangzhou, China) [19].
Statistical Analysis
Statistical significance was evaluated using a one-tailed, two-
sample Student’s t test. P≤0.05 was considered statistically
significant.
Results
Establishment of PDGAX Mouse Models
Age, gender and tumor characteristics from five GA patients
were collated (Table 1). All five patients’ GA samples were
viable and led to growth in SCID mice after subcutaneous
implantation, and continued to grow in nude mice after the
second generation. The growth curves of the five established
PDGAX mouse models are shown in Fig. 1. Autopsy
examination of all PDGAX tumor-bearingmice at 2–3months
post-implantation revealed no evidence of metastases in the
stomach, brain, lung, liver or kidney.
Histology and Tumor Grade
All five PDGAX mouse models and their corresponding pa-
tient’s GA tissues were classified as gastric adenocarcinoma
by pathologist histological evaluation. Similar histological
features were observed between each xenograft model and
its corresponding patient GA tissue (Fig. 2).
Characterization of HER-2 Protein and Gene Expression
in PDGAX Models
Following Hoffman’s HER-2 scoring criteria [16], three
PDGAX mouse models (PDGAX001, PDGAX003 and
PDGAX005) were scored as strongly positive for HER-2
membrane staining (3+), one model (PDGAX002) was scored
as moderately positive (2+), and one model (PDGAX004)
was scored as HER-2 negative (Fig. 3). According to
Hoffman’s criteria, the scoring of HER-2 gene copy number
determined by FISH assay was ‘score 6’ (gene amplification)
for models PDGAX001 and PDGAX005, ‘score 5’ for model
PDGAX002, and ‘score 2’ for models PDGAX003 and
PDGAX004. However, only model PDGAX005 showed a
gene copy number increase with an average copy number of
more than 20, whereas the average gene copy numbers of the
other models were less than 6.0. In addition, all five PDGAX
mouse models and their corresponding patient GA tissues
showed a highly similar pattern of HER-2 protein expression
and gene copy number (Fig. 3).







with vehicle control group. No
modulation observed in model
PDGAX001
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Antitumor Efficacy of Trastuzumab in PDGAX Mouse
Models
Trastuzumab anti-tumor efficacy studies were performed
using a twice per week dosing schedule (15 mg/kg, i.p.) in
all five PDGAX mouse models (Fig. 4 and Table 1).
Three PDGAX models (PDGAX002, 003, and 004),
which did not fit the current eligibility criteria for
trastuzumab, showed either no or partial responses to
trastuzumab treatment (PDGAX002, 0 % TGI, P=
0.3321; PDGAX003, 26 % TGI, P=0.0627; PDGAX004,
9 % TGI, P=0.3303). As expected, in model PDGAX005
(HER2 FISH AMP, IHC 3+, average gene copy number>
20), treatment with trastuzumab induced significant tumor
regression (105 % TGI, P<0.0001). Surprisingly, howev-
er, model PDGAX001 (HER2 FISH AMP, IHC 3+) failed
to respond to trastuzumab (19 % TGI, P=0.0904), despite
evidence of strong HER2 protein expression and fulfill-
ment of the clinical trastuzumab eligibility criteria. To
further explore this finding, we sought to detect gene mu-
tations that may confer resistance to trastuzumab.
Pharmacodynamic Modulation of pHER2 by Trastuzumab
pHER2 IHC was performed on vehicle control and
trastuzumab treatment groups from PDGAX001 and
PDGAX005 efficacy studies, both of which were HER2
IHC 3+ and HER2 FISH AMP, but displayed very different
responses to trastuzumab. As expected, clear pHER2 modu-
lation was observed in trastuzumab-treated tissues frommodel
PDGAX005, but not in model PDGAX001 (Fig. 5), indicat-
ing that pharmacodynamic modulation of pHER2 correlates to
trastuzumab response in model PDGAX005.
Gene Mutation Screening
A panel of genes including; AKT1, FGFR4, PIK3CA, PTCH,
PTEN, TP53 were screened in all of the PDGAX mouse
models and corresponding patient GA tissues. Interestingly,
the TP53 mutation was identified in exon 5 from both the
PDGAX001 model and the corresponding patient GC tissue.
This was subsequently confirmed by direct sequencing
(Fig. 6). A mutation (G ->A) was identified which causes an
amino acid change from cysteine to tyrosine at the 176th pep-
tide of TP53 protein. The functional meaning of this mutation
is unclear. No other mutations were detected in the PDGAX
models or their corresponding patient GA tissue.
Discussion
Considering the current economic and ethical issues within
modern drug discovery, relevant and predictive animal models
of human cancer are immensely important in the search for
new therapeutics. Subcutaneous tumor implantation has been
the standard methodology in establishing animal models for
human cancer research [20, 21]. However, standard xeno-
grafts make use of permanent tumor cell lines instead of pri-
mary tumors, and often have poor predictive value in deter-
mining human drug efficacy [22]. PDGAX models more
closely resemble primary human tumors in terms of tissue
architecture and molecular heterogeneity and thus offer the
potential to better predict drug efficacy in humans [22]. To
date, few PDGAX mouse models have been successfully
established from GA patient tissues. Herein, we have success-
fully created five PDGAX mouse models by directly
implanting fresh GA patient tissues into immune deficient
mice. All five PDGAXmouse models and their corresponding
Fig. 6 TP53 gene mutation detected by PCR-direct sequencing. An
illustration of the mutation (G ->A) identified in TP53 gene (both on
forward and reverse sequences). This mutation led to an amino acid
change from cysteine to tyrosine at the 176th peptide of TP53 protein
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patients’ gastric cancer tissues displayed a highly similar pat-
tern in HER-2 protein expression and gene copy number. This
finding gives further support to the hypothesis that PDGAX
mouse models can more accurately represent clinical disease.
Furthermore, we have used these PDGAX mouse models to
successfully evaluate the efficacy of trastuzumab in gastric
adenocarcinoma.
An excellent correlation between trastuzumab efficacy and
HER-2 expression/ amplification has been shown in advanced
gastric and gastroesophageal junction (GEJ) adenocarcinoma
patients by the ToGA trials [1] and other previous studies [23].
According to the latest clinical practice guidelines [1, 14, 24],
trastuzumab, in combination with cisplatin and a
fluoropyrimidine, is recommended for advanced HER-2 pos-
itive GC. For clinicians, accurate and reliable identification of
patients eligible for HER-2 targeted therapy is of crucial im-
portance. The algorithm proposed by Hoffmann [16] incorpo-
rates a combination of IHC and FISH analyses and is the most
appropriate HER-2 scoring system currently in use for the
identification of trastuzumab-eligible gastric cancer patients.
HER-2 positivity is defined as either IHC positive (3+) or
FISH positive (HER-2/CEN-17≥2.2 or HER-2 gene copy
number≥6). However, according to the results of the ToGA
trial, there is little difference in the proposed algorithm for
HER-2 testing in gastric cancer between the FDA in the US
and the European Medicines Agency [14]. Furthermore, there
is no apparent benefit in patients with IHC 0 to 1+/FISH
positive disease, suggesting that an IHC assay may be better
suited to the selection of patients for treatment with
trastuzumab [14]. In our study, two models (PDGAX001
and PDGAX005) were identified as HER-2 positive by
IHC3+ and FISH AMP. Our data demonstrated significant
tumor regression after treatment with trastuzumab in model
PDGAX005 model (with a higher average gene copy num-
ber), but not in PDGAX001model (with a lower average gene
copy number).
To explore the mechanism underlying the difference in
trastuzumab anti-tumor efficacy between the two HER-2
IHC 3+ and FISH AMP PDGAX models (PDGAX005 and
PDGAX001), molecular genetic studies were performed. Af-
ter screening gene mutations in AKT1, FGFR4, PIK3CA,
PTCH, PTEN and TP53 in the 5 PDGAX mouse models
and their corresponding primary tumors, mutation of TP53
was identified in model PDGAX001 and the corresponding
patient tissue (Fig. 4 and Table 1). This result suggested that
TP53 mutation might represent a mechanism through which
trastuzumab resistance may be conferred. Further work is on-
going to explore the mechanism underneath.
In summary, we have established novel xenograft models
derived from patient gastric adenocarcinoma tissues and used
these clinically relevant animal models to investigate the cor-
relation of trastuzumab anti-tumor efficacy with HER-2 ex-
pression. Our results showed that PDGAX models could
accurately recapitulate trastuzumab clinical data in the preclin-
ical setting, underscoring their predictive power for future
drug discovery.
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